Daily briefing · 2026-09-19

Mutation-targeted RNA treatment shows early promise in one ALS patient

A physician with a slowly progressing inherited form of ALS showed improved motor scores and normalized levels of a neuronal-damage biomarker one year after starting an antisense treatment tailored to his rare CHCHD10 mutation. Six doses were administered between April 2024 and April 2025 without serious reported side effects. The single-patient result suggests individualized RNA therapies may be feasible, but it does not establish lasting effectiveness or a cure. First for RNA therapy: man with rare motor-neuron disease improves after treatment

Anthropic confirms physical biology laboratory

Anthropic confirmed that it operates a wet laboratory in the San Francisco Bay Area, where it is exploring how Claude can support experiments and direct robotic equipment with human oversight. The company said the facility is not specifically a drug-discovery lab and disclosed no experimental results. Connecting AI-generated proposals with physical tests could aid scientific research, though reliable discoveries or substantial efficiency gains have yet to be demonstrated. Anthropic quietly sets up biology lab as it ramps AI drug program

Genomic study recognizes Bolivia’s tilcayo as a distinct wild cat

Researchers formally described Leopardus tilcayo as a distinct species after comparing genomes from more than 30 living and museum-preserved South American cats. The lineage appears to have separated from relatives about 1.4 million years ago, although communities in Bolivia’s Yungas cloud forests already knew the animal. Recognition clarifies tiger-cat diversity, but the tilcayo’s population, ecology and full range remain unknown, limiting assessment of its conservation needs. A new cat species is discovered for the first time in over a century